Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29053200 | 0.88 | HDAC1 (0.48) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3313893 | 0.86 | GAA (0.41) | MAOBCYP1A2TSHRNFKB1MEN1 | |
| SCHEMBL29230045 | 0.85 | SMN1; SMN2 (0.55) | MAOBCYP1A2TSHRNFKB1KMT2A | |
| SCHEMBL1415854 | 0.85 | POLB (0.46) | KMT2AKDM4ESPHK2SMN1; SMN2LMNA | |
| SCHEMBL29104753 | 0.84 | SMN1; SMN2 (0.57) | MAOBCYP1A2TSHRNFKB1KMT2A | |
| SCHEMBL1490709 | 0.83 | L3MBTL1 (0.55) | TSHRKMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL8010684 | 0.81 | EPHX2 (0.47) | SMN1; SMN2LMNAPOLBNPC1RAB9A | |
| SCHEMBL4318844 | 0.81 | SMN1; SMN2 (0.64) | TSHRSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL1416098 | 0.81 | HPGD (0.59) | CYP1A2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL10716721 | 0.80 | KDM4E (0.48) | CYP1A2BLMPMP22KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | claimed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | claimed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| CN-1829513-A | 5-membered heterocycle-based p-38 inhibitors | NOVARTIS AG (CH) | 2006-09-06 | — | — | CN | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| CN-110312522-A | - 1 inhibitor of lysine specific histone demethylation enzyme and application thereof | 堪培拉大学 | 2019-10-08 | — | — | CN | disclosed |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-08-29 | — | — | US | disclosed |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | UNIVERSITY OF CANBERRA (AU) | 2019-03-05 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| CN-107106517-A | Compositions for modulating cancer stem cells and uses thereof | 堪培拉大学 | 2017-08-29 | — | — | CN | disclosed |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | EpiAxis Therapeutics Pty Ltd. (AU) | 2016-05-26 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| CN-1829513-A | 5-membered heterocycle-based p-38 inhibitors | NOVARTIS AG (CH) | 2006-09-06 | — | — | CN | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | MAOB 2259/4885CYP1A2 4527/4885TSHR 4333/4885 |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | MAOB 2932/4885CYP1A2 4567/4885TSHR 4190/4885 |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | MAOB 2932/4885CYP1A2 4567/4885TSHR 4190/4885 |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | MAOB 2932/4885CYP1A2 4567/4885TSHR 4190/4885 |
| US-20100004298-A1 | P-38 INHIBITORS | MAPK8, MAPK1, MAP3K8 | MAOB 3703/4885CYP1A2 1800/4885TSHR 4297/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | MAOB 3605/4885CYP1A2 2097/4885TSHR 4490/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | MAOB 36/4885CYP1A2 1176/4885TSHR 1775/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | MAOB 2259/4885CYP1A2 4527/4885TSHR 4333/4885 |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | MAOB 2932/4885CYP1A2 4567/4885TSHR 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.